Clinical Trial

Effect of Zinc on Glucose Homeostasis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this investigation is to evaluate the impact of zinc supplementation on fasting glucose levels, hemoglobin A1c (HbA1c), and other indices of glucose homeostasis in individuals with prediabetes. The investigators hypothesize that prediabetic subjects receiving zinc will demonstrate a greater decrease in HbA1c and blood glucose compared to prediabetic subjects receiving placebo. Specific Aim: Conduct a prospective, double-blind randomized clinical trial comparing the effects of 12 months of zinc supplementation (zinc gluconate 30 milligram \[mg\] per day) versus placebo on glucose homeostasis. Based upon expected effect size and power calculations, and anticipating a 20% drop-out rate, the investigators will study 200 prediabetic subjects (100 per group) using a 1:1 randomization design. HbA1c, fasting plasma glucose, and other measures will be obtained at 0, 6, and 12 months and will be compared between zinc supplementation and placebo groups.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-04-17; most recent amendment 2026-07-08.
Status change: Not Yet Recruiting → Recruiting 2024-04-10
Trial Details
NCT Number NCT05835037
Lead Sponsor University of Maryland, Baltimore
Conditions Prediabetic State, Hyperglycemia
Enrollment 200 participants
Start Date 2024-02-16
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-10